文献速递淋巴瘤

安大略省惰性淋巴瘤患者接受苯达莫司汀联合利妥昔单抗对比利妥昔单抗联合CVP或CHOP化学免疫治疗的结局

Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
PubMed 文献 · Br J Haematol · 2023-07-20

在加拿大安大略省开展倾向匹配回顾性队列人群研究,比较2005-2012年接受R-CVP/CHOP与2013-2018年接受BR的惰性淋巴瘤患者。BR组5年OS为80%,R-CVP/CHOP组为75%,BR与OS改善相关(HR 0.79,95%CI 0.69-0.91)。BR组前9个月感染入院率(22% vs 17%,p<0.01)和急诊就诊均值(1.01±1.68 vs 0.85±1.51次,p<0.01)更高。

要点

  • BR组5年OS 80%,R-CVP/CHOP组75%,BR与OS改善相关(HR 0.79,95%CI 0.69-0.91)。
  • BR组前9个月感染入院率22% vs R-CVP/CHOP组17%(p<0.01)。
  • ≥75岁患者调整后5年OS两组无差异(BR 55.5% vs R-CVP/CHOP 55.4%)。

核心结论

  • 研究支持对需要治疗的惰性淋巴瘤患者使用BR,但提示某些毒性风险增加,需仔细选择患者。

研究设计与样本

  • 倾向匹配回顾性队列人群研究,纳入2005-2012年接受R-CVP/CHOP和2013-2018年接受BR的患者。
  • BR组2023例,R-CVP/CHOP组2023例,主要终点为5年OS,次要终点包括毒性和医疗资源利用。

主要发现

  • BR组5年OS为80%,R-CVP/CHOP组为75%,BR与OS改善相关(HR 0.79,95%CI 0.69-0.91)。
  • 前9个月BR组感染入院率22%,R-CVP/CHOP组17%(p<0.01)。
  • 前9个月BR组急诊就诊均值1.01±1.68次,R-CVP/CHOP组0.85±1.51次(p<0.01)。
  • 该趋势持续3年。
  • ≥75岁患者调整后5年OS两组无差异(BR 55.5% vs R-CVP/CHOP 55.4%)。

临床怎么用

  • 作者结论支持对需要治疗的惰性淋巴瘤患者使用BR,但提示某些毒性风险增加,需仔细选择患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bendamustine (B) with rituximab (R) has become the preferred regimen for patients with indolent lymphoma in Ontario, Canada, compared to R with cyclophosphamide, vincristine, prednisone (CVP) or cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). We conducted a propensity-matched retrospective cohort population-based study of patients treated with R-CVP/CHOP from 2005 to 2012 and patients treated with BR from 2013 to 2018. The primary outcome was 5-year overall survival (OS), and secondary outcomes included toxicities and healthcare utilization. The 5-year OS for patients treated with BR (n = 2023) and R-CVP/CHOP (n = 2023) was 80% and 75% respectively. Treatment with BR was associated with improved OS (HR 0.79, 95% CI 0.69-0.91). During the first 9 months, patients treated with BR versus R-CVP/CHOP had a higher number of admissions for infection (22% compared to 17%, p < 0.01) and a higher number of mean ED visits (mean 1.01 ± 1.68 visits vs. 0.85 ± 1.51 visits, p < 0.01). This trend persisted for 3 years. The adjusted 5-year OS for patients 75 years and older did not differ based on treatment regimen (55.5% for BR vs. 55.4% for R-CVP/CHOP). Our study supports the use of BR for patients with indolent lymphoma requiring treatment but suggests increased risk of certain toxicities warranting careful patient selection.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Suleman A, Aktar SJ, Ante Z, et al. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario. Br J Haematol. 2023. PMID: 37474340. doi:10.1111/bjh.18972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。